A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 26, 2022

Primary Completion Date

December 5, 2023

Study Completion Date

December 5, 2023

Conditions

Patients with Mild or Moderate Hepatic Impairment

Interventions

DRUG

TS-142 5 mg

Single-dose of 5 mg of TS-142

Trial Locations (1)

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors

lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY